Metamorphoses of Lyme disease spirochetes: phenomenon of Borrelia persisters.


Journal

Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774

Informations de publication

Date de publication:
16 May 2019
Historique:
received: 14 02 2019
accepted: 09 05 2019
entrez: 18 5 2019
pubmed: 18 5 2019
medline: 13 7 2019
Statut: epublish

Résumé

The survival of spirochetes from the Borrelia burgdorferi (sensu lato) complex in a hostile environment is achieved by the regulation of differential gene expression in response to changes in temperature, salts, nutrient content, acidity fluctuation, multiple host or vector dependent factors, and leads to the formation of dormant subpopulations of cells. From the other side, alterations in the level of gene expression in response to antibiotic pressure leads to the establishment of a persisters subpopulation. Both subpopulations represent the cells in different physiological states. "Dormancy" and "persistence" do share some similarities, e.g. both represent cells with low metabolic activity that can exist for extended periods without replication, both constitute populations with different gene expression profiles and both differ significantly from replicating forms of spirochetes. Persisters are elusive, present in low numbers, morphologically heterogeneous, multi-drug-tolerant cells that can change with the environment. The definition of "persisters" substituted the originally-used term "survivors", referring to the small bacterial population of Staphylococcus that survived killing by penicillin. The phenomenon of persisters is present in almost all bacterial species; however, the reasons why Borrelia persisters form are poorly understood. Persisters can adopt varying sizes and shapes, changing from well-known forms to altered morphologies. They are capable of forming round bodies, L-form bacteria, microcolonies or biofilms-like aggregates, which remarkably change the response of Borrelia to hostile environments. Persisters remain viable despite aggressive antibiotic challenge and are able to reversibly convert into motile forms in a favorable growth environment. Persisters are present in significant numbers in biofilms, which has led to the explanation of biofilm tolerance to antibiotics. Considering that biofilms are associated with numerous chronic diseases through their resilient presence in the human body, it is not surprising that interest in persisting cells has consequently accelerated. Certain diseases caused by pathogenic bacteria (e.g. tuberculosis, syphilis or leprosy) are commonly chronic in nature and often recur despite antibiotic treatment. Three decades of basic and clinical research have not yet provided a definite answer to the question: is there a connection between persisting spirochetes and recurrence of Lyme disease in patients?

Identifiants

pubmed: 31097026
doi: 10.1186/s13071-019-3495-7
pii: 10.1186/s13071-019-3495-7
pmc: PMC6521364
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

237

Subventions

Organisme : Ministry of Education, Youth and Sport of the Czech Republic
ID : CZ.02.1.01/0.0/0.0/16_013/0001775
Organisme : Ministry of Education, Youth and Sport of the Czech Republic
ID : LM2015062 Czech-BioImaging
Organisme : Ministry of Health of the Czech Republic
ID : NV19-05-00191

Références

APMIS. 1998 Dec;106(12):1131-41
pubmed: 10052721
Science. 1999 May 21;284(5418):1318-22
pubmed: 10334980
Infect Immun. 1999 Jul;67(7):3181-7
pubmed: 10377088
Ann Med. 1999 Jun;31(3):225-32
pubmed: 10442678
Curr Opin Microbiol. 1999 Dec;2(6):582-7
pubmed: 10607620
Microbiology. 2000 Jan;146 ( Pt 1):119-27
pubmed: 10658658
J Infect Dis. 2000 Mar;181(3):1069-81
pubmed: 10720533
Annu Rev Microbiol. 2000;54:49-79
pubmed: 11018124
Trends Microbiol. 2001 Jan;9(1):34-9
pubmed: 11166241
Br J Dermatol. 2001 Feb;144(2):387-92
pubmed: 11251580
Antimicrob Agents Chemother. 2001 Apr;45(4):999-1007
pubmed: 11257008
N Engl J Med. 2001 Jul 12;345(2):115-25
pubmed: 11450660
APMIS. 2001 May;109(5):383-8
pubmed: 11478686
Mol Microbiol. 2001 Jul;41(2):463-76
pubmed: 11489131
Clin Microbiol Rev. 2002 Apr;15(2):167-93
pubmed: 11932229
J Clin Microbiol. 2002 Nov;40(11):4256-65
pubmed: 12409407
Infect Immun. 2003 Sep;71(9):5042-55
pubmed: 12933847
FEMS Microbiol Lett. 2004 Jan 15;230(1):13-8
pubmed: 14734160
APMIS. 2004 Jan;112(1):57-62
pubmed: 14961976
Microbes Infect. 2004 Mar;6(3):312-8
pubmed: 15065567
Cent Eur J Public Health. 2004 Mar;12(1):6-11
pubmed: 15068199
FEMS Microbiol Lett. 2004 Jul 15;236(2):163-73
pubmed: 15251193
Microbiology. 2004 Jul;150(Pt 7):2401-7
pubmed: 15256581
Am J Pathol. 2004 Sep;165(3):977-85
pubmed: 15331421
Lancet Infect Dis. 2004 Sep;4(9):575-83
pubmed: 15336225
Lab Invest. 2004 Nov;84(11):1439-50
pubmed: 15448708
Trends Microbiol. 2005 Jan;13(1):20-6
pubmed: 15639628
Antimicrob Agents Chemother. 2005 Apr;49(4):1294-301
pubmed: 15793100
Vet Microbiol. 2005 May 20;107(3-4):285-94
pubmed: 15863289
Annu Rev Cell Dev Biol. 2005;21:319-46
pubmed: 16212498
Microbiol Mol Biol Rev. 2005 Dec;69(4):527-43
pubmed: 16339734
Appl Environ Microbiol. 2006 Jan;72(1):392-7
pubmed: 16391069
Microbes Infect. 2006 Apr;8(5):1390-9
pubmed: 16698304
Microbes Infect. 2006 Jul;8(8):2044-51
pubmed: 16797205
Biotechnol Lett. 2006 Nov;28(21):1701-12
pubmed: 16912921
Clin Infect Dis. 2006 Nov 1;43(9):1089-134
pubmed: 17029130
J Infect Dis. 2007 May 15;195(10):1489-96
pubmed: 17436229
Trends Microbiol. 2007 Aug;15(8):350-4
pubmed: 17600717
Trends Parasitol. 2007 Sep;23(9):434-8
pubmed: 17656156
Antimicrob Agents Chemother. 2008 May;52(5):1728-36
pubmed: 18316520
Microbiology. 2008 May;154(Pt 5):1309-17
pubmed: 18451039
Infect Dis Clin North Am. 2008 Jun;22(2):217-34, v
pubmed: 18452798
J Neuroinflammation. 2008 Sep 25;5:40
pubmed: 18817547
Infect Immun. 1991 Jan;59(1):302-8
pubmed: 1898898
G Ital Dermatol Venereol. 2009 Apr;144(2):157-71
pubmed: 19357623
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18656-61
pubmed: 19843691
J Infect Dis. 1991 Feb;163(2):311-8
pubmed: 1988514
J Clin Invest. 2009 Dec;119(12):3652-65
pubmed: 19920352
Antimicrob Agents Chemother. 2010 Feb;54(2):643-51
pubmed: 19995919
Int J Syst Evol Microbiol. 2011 Jan;61(Pt 1):110-7
pubmed: 20173011
Infect Immun. 1991 Jun;59(6):1916-21
pubmed: 2037352
Annu Rev Microbiol. 2010;64:357-72
pubmed: 20528688
J Clin Microbiol. 1991 May;29(5):894-6
pubmed: 2056054
APMIS. 2010 Sep 1;118(9):665-73
pubmed: 20718718
Infection. 1990 Nov-Dec;18(6):332-41
pubmed: 2076905
J Am Vet Med Assoc. 2010 Nov 15;237(10):1180-5
pubmed: 21073390
Vet Pathol. 2011 Nov;48(6):1151-7
pubmed: 21285382
Am J Trop Med Hyg. 1990 Feb;42(2):165-74
pubmed: 2138431
J Med Microbiol. 2011 Jun;60(Pt 6):699-709
pubmed: 21459912
N Engl J Med. 1990 Nov 22;323(21):1438-44
pubmed: 2172819
Infect Drug Resist. 2011;4:97-113
pubmed: 21753890
Annu Rev Microbiol. 2011;65:479-99
pubmed: 21801026
PLoS One. 2012;7(1):e29914
pubmed: 22253822
PLoS Pathog. 2012 Feb;8(2):e1002532
pubmed: 22359504
BMC Microbiol. 2012 Mar 23;12:44
pubmed: 22443136
J Clin Invest. 2012 Jul;122(7):2652-60
pubmed: 22728937
Ann Intern Med. 2012 Aug 7;157(3):ITC2-2 - ITC2-16
pubmed: 22868858
PLoS One. 2012;7(10):e48277
pubmed: 23110225
MBio. 2012 Dec 04;3(6):e00434-12
pubmed: 23221801
Front Microbiol. 2013 Apr 30;4:103
pubmed: 23641241
PLoS One. 2014 Jan 23;9(1):e86907
pubmed: 24466286
Microbiology. 2015 Mar;161(Pt 3):516-27
pubmed: 25564498
F1000Prime Rep. 2015 Jan 05;7:11
pubmed: 25705394
PLoS One. 2015 Mar 25;10(3):e0117207
pubmed: 25806811
Parasit Vectors. 2015 Mar 13;8:155
pubmed: 25886272
Antimicrob Agents Chemother. 2015 Aug;59(8):4616-24
pubmed: 26014929
Emerg Microbes Infect. 2014 Jan;3(1):e3
pubmed: 26038493
Emerg Microbes Infect. 2014 Jul;3(7):e49
pubmed: 26038747
Infection. 1989 Nov-Dec;17(6):355-9
pubmed: 2613324
Antimicrob Agents Chemother. 2015 Oct;59(10):6288-95
pubmed: 26248368
PLoS Pathog. 2015 Sep 15;11(9):e1005160
pubmed: 26371761
Emerg Microbes Infect. 2015 Aug;4(8):e51
pubmed: 26421273
Clin Microbiol Infect. 2016 Mar;22(3):267.e9-15
pubmed: 26673735
Eur J Microbiol Immunol (Bp). 2015 Nov 12;5(4):268-80
pubmed: 26716015
Eur J Microbiol Immunol (Bp). 2016 Feb 09;6(1):9-24
pubmed: 27141311
Front Microbiol. 2016 May 23;7:743
pubmed: 27242757
Front Immunol. 2016 Sep 26;7:385
pubmed: 27725820
Front Med (Lausanne). 2017 Oct 11;4:169
pubmed: 29075628
Am J Clin Pathol. 1989 Jan;91(1):95-7
pubmed: 2910019
PLoS One. 2017 Dec 13;12(12):e0189071
pubmed: 29236732
Healthcare (Basel). 2018 Apr 14;6(2):null
pubmed: 29662016
Antibiotics (Basel). 2018 Oct 16;7(4):null
pubmed: 30332754
N Engl J Med. 1988 Dec 1;319(22):1441-6
pubmed: 3054554
J Am Acad Dermatol. 1986 Sep;15(3):459-63
pubmed: 3093544
Pediatr Infect Dis J. 1988 Apr;7(4):286-9
pubmed: 3130607
J Infect Dis. 1988 Oct;158(4):905-6
pubmed: 3171237
Arthritis Rheum. 1988 Apr;31(4):487-95
pubmed: 3258751
J Clin Microbiol. 1988 May;26(5):893-5
pubmed: 3290239
JAMA. 1988 May 13;259(18):2737-9
pubmed: 3357244
J Clin Microbiol. 1987 Nov;25(11):2054-8
pubmed: 3693538
Proc Soc Exp Biol Med. 1986 Feb;181(2):263-9
pubmed: 3945634
J Gen Virol. 1967 Oct;1(4):575-6
pubmed: 6081706
Sci Am. 1978 Jan;238(1):86-95
pubmed: 635520
Antimicrob Agents Chemother. 1995 May;39(5):1127-33
pubmed: 7625800
Eur Neurol. 1995;35(2):113-7
pubmed: 7796837
Lab Invest. 1995 Feb;72(2):146-60
pubmed: 7853849
Ann Intern Med. 1994 Oct 15;121(8):560-7
pubmed: 8085687
J Clin Neuroophthalmol. 1993 Sep;13(3):155-61; discussion 162
pubmed: 8106639
Arthritis Rheum. 1993 Nov;36(11):1621-6
pubmed: 8240439
Clin Orthop Relat Res. 1993 Dec;(297):238-41
pubmed: 8242938
N Engl J Med. 1994 Jan 27;330(4):229-34
pubmed: 8272083
Am J Pathol. 1993 Sep;143(3):959-71
pubmed: 8362988
Infection. 1993 Mar-Apr;21(2):83-8
pubmed: 8387966
Infect Immun. 1993 Nov;61(11):4777-84
pubmed: 8406878
J Urol. 1993 Jan;149(1):26-30
pubmed: 8417211
J Am Acad Dermatol. 1993 Feb;28(2 Pt 2):312-4
pubmed: 8436647
Annu Rev Microbiol. 1995;49:711-45
pubmed: 8561477
Ann Intern Med. 1977 Jun;86(6):685-98
pubmed: 869348
J Infect Dis. 1996 Sep;174(3):623-7
pubmed: 8769624
Infection. 1996 May-Jun;24(3):218-26
pubmed: 8811359
Infection. 1996 Jan-Feb;24(1):9-16
pubmed: 8852456
Infection. 1996 Jan-Feb;24(1):64-8
pubmed: 8852473
Infection. 1996 Jan-Feb;24(1):73-5
pubmed: 8852475
Rheumatol Int. 1996;16(3):125-32
pubmed: 8893378
Infection. 1996 Sep-Oct;24(5):347-53
pubmed: 8923044
J Clin Microbiol. 1997 Jan;35(1):111-6
pubmed: 8968890
Am J Dermatopathol. 1996 Dec;18(6):571-9
pubmed: 8989928
Brain. 1996 Dec;119 ( Pt 6):2143-54
pubmed: 9010017
Infection. 1997 Jul-Aug;25(4):240-6
pubmed: 9266264
J Clin Invest. 1998 May 15;101(10):2240-50
pubmed: 9593780
Microbiology. 1998 May;144 ( Pt 5):1133-43
pubmed: 9611788
Ann Rheum Dis. 1998 Feb;57(2):118-21
pubmed: 9613343
Med J Aust. 1998 May 18;168(10):500-2
pubmed: 9631675
J Infect Dis. 1998 Sep;178(3):722-32
pubmed: 9728541

Auteurs

Natalie Rudenko (N)

Biology Centre CAS, Institute of Parasitology, Branisovska 31, 37005, Ceske Budejovice, Czech Republic. natasha@paru.cas.cz.

Maryna Golovchenko (M)

Biology Centre CAS, Institute of Parasitology, Branisovska 31, 37005, Ceske Budejovice, Czech Republic.

Katerina Kybicova (K)

National Institute of Public Health, Srobarova 48, 100 42, Prague 10, Czech Republic.

Marie Vancova (M)

Biology Centre CAS, Institute of Parasitology, Branisovska 31, 37005, Ceske Budejovice, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH